Interleukin-1 blockade with anakinra in acute leukaemia patients with severe COVID-19 pneumonia appears safe and may result in clinical improvement

Br J Haematol. 2020 Jul;190(2):e80-e83. doi: 10.1111/bjh.16873. Epub 2020 Jun 10.

Authors

James W Day^{1

2}, Thomas A Fox^{1

2}, Richard Halsey¹, Ben Carpenter¹, Panagiotis D Kottaridis¹

Affiliations

¹ Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK.
² UCL Institute of Immunity and Transplantation, UCL, London, UK.

No abstract available

Keywords: acute leukaemia; haemophagocytic syndrome; immunotherapy; infection.

Publication types

Case Reports
Letter

MeSH terms

Adult
Betacoronavirus
COVID-19
Coronavirus Infections / complications*
Humans
Interleukin 1 Receptor Antagonist Protein / therapeutic use*
Interleukin-1 / antagonists & inhibitors*
Leukemia / drug therapy*
Male
Pandemics
Pneumonia, Viral / complications*
SARS-CoV-2

Substances

Interleukin 1 Receptor Antagonist Protein
Interleukin-1